Skip to content
Sitemapadmin2019-12-05T14:52:14+00:00
Pages
Posts by category
- Category: David Garrity
- Category: News
- Laidlaw acts as Co-Manager on the $287,500,000 Follow-On Offering for Viking Therapeutics.
- Laidlaw acts as Exclusive Placement Agent on the $9,200,000 Private Placement for Guerrilla RF
- Laidlaw acts as Joint Book Runner on the $7,000,000 Initial Public Offering for NFT Gaming Company
- Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
- Laidlaw acts as Sole Placement Agent on the $4,000,000 NLS Pharmaceutics Ltd. Private Placement
- Laidlaw acts as Sole Book-Runner on the $5,750,000 Silo Pharma, Inc. Follow-On Offering
- Laidlaw Capital Markets is pleased to announce the closing of its expanded and oversubscribed $10,000,000 financing for Perfect Moment.
- Laidlaw acts as Sole-Book Runner on the $3,500,000 BioSig Technologies’ Follow-On Transaction.
- Laidlaw acts as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering
- Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.
- Laidlaw Capital Markets is Financial Advisor on MEI Pharma Inc’s $52,325,000 Follow-On Offering
- Laidlaw Capital Markets is Financial Advisor on EyePoint Pharmaceuticals Inc’s $115,400,000 Follow-On Offering.
- Laidlaw Capital Markets is Co-Manager in Guggenheim Active Allocation Fund Initial Public Offering
- Laidlaw Capital Markets is Co-Manager in Blackrock ESG Capital Allocation Trust $2,040,000,000 Initial Public Offering
- Laidlaw Capital Markets is Lead Manager in aTyr Pharma’s (LIFE) $86,250,000. Offering.
- Laidlaw Capital Markets is pleased to have acted as Sole Book-Runner on the $10,000,000 Follow-On Offering for BioSig Technologes (BSGM).
- How advisor platforms are changing the offshore industry
- Laidlaw expands international business with new Miami-area office
- Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $125,000,000 Follow-On Offering for Aldeyra Therapeutics.
- Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
- Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $25,000,000 Follow-On Offering for iCAD Inc.
- Laidlaw Venture Partners Portfolio Company, AerWave Medical, Inc., Closes $4,000,000 Series A Financing Round.
- Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint Pharmaceuticals
- Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman.
- Laidlaw served as Co-Manager on the $115,000,000 Offering for Affimed (AFMD)
- Laidlaw served as Sole Book-Runner on the $14,375,000 Offering for Evoke Pharma (EVOK)
- Laidlaw served as Financial Advisor on the $20,000,000 Offering for Delcath Systems (DCTH)
- Laidlaw served as Lead Manager on the $147,500,000 Offering for Curis Inc (CRIS)
- Laidlaw Venture Partners portfolio company, Amesite (Nasdaq Ticker, AMST), CEO Ann Marie Sastry on Fox Business News today
- Laidlaw Wealth Management Acquires Naples Wealth Planning
- Laidlaw Venture Partners portfolio company Amesite (AMST) announces pricing of Initial Public Offering of $15,000,000.
- Laidlaw Venture Partners Continues Strategic Growth with Addition of Mr. Anthony Zook to its Investment and Operations Committee
- Laidlaw served as Financial Advisor on the $173,000,000 Follow-On Offering for Arcturus Therapeutics (ARCT)
- Laidlaw Venture Partners’ portfolio company Amesite CEO, Dr. Ann Marie Sastry, back on CNBC’s Squawk Box.
- Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors
- Laidlaw served as Co-Manager on the $50,000,000 Follow-On Offering for Soleno Therapeutics (SLNO) with Guggenheim Partners
- Laidlaw Venture Partners Adds Industry Leading CEOs Jeffrey O’Donnell and Dr. Ann Marie Sastry to its Board of Advisors
- Laidlaw served as Sole Book-Runner on the $5mm Follow-On Offering for Hoth Therapeutics (HOTH)
- Laidlaw served as Introducing Broker on the $10.8mm financing for Biosig Technologies (BSGM), through its subsidiary ViralClear.
- Laidlaw served as Co-Lead Manager on the $22mm financing and uplisting for Delcath Systems (DCTH)
- Laidlaw served as Financial Advisor on the $70mm Follow-On Offering for Arcturus Therapeutics (ARCT).
- A BRIGHTER FUTURE, with Laidlaw episode #6: Laidlaw Five with David Garrity (Session 4)
- A BRIGHTER FUTURE, with Laidlaw. Episode #5 Laidlaw Five with David Garrity Session 3 episode of A Brighter Future
- Laidlaw & Company enhances their Wealth Management offering with Envestnet | MoneyGuide
- How artificial intelligence can control disease outbreaks
- Laidlaw served as Co-Manager on the $21.75mm EyePoint Pharmaceuticals (EYPT) Follow-On Offering.
- Laidlaw served as Sole Book-Runner on the $10mm BioSig Technologies (BSGM) Follow-On Offering.
- Defiance ETFs LLC Rings The Closing Bell®
- Laidlaw served as Co-Manager on the $90mm Ziopharm Oncology (ZIOP) Follow-On Offering
- The Laidlaw Five. Behind the Numbers.
- Wealth management’s newest competitor is 177 years old
- Laidlaw Helps Amesite Inc. Raise $5.5 Million in Oversubscribed Financing Round
- Laidlaw served as Financial Advisor on the $11.5mm Beyond Air (XAIR) Follow-On Offering
- Laidlaw Wealth Management Boosts Investment Offering With Green Harvest Deal
- Laidlaw served as Co-Manager on the $34.5mm Affimed (AFMD) Follow-On Offering
- Laidlaw served as Financial Advisor on the $50mm Molecular Templates (MTEM) Follow-On Offering
- Laidlaw’s ‘Brighter Future’ Comes Into Focus; Richard Calhoun, Former Wells Senior Executive, Brought on as CEO of Laidlaw Wealth Management
- Laidlaw served as Co-Manager on the $15.4mm Soleno (SLNO) Follow-On Offering
- Seven Questions with Tony Sirianni
- Laidlaw on a Recruiting Tear in 2019
- Category: Podcasts
- Category: press release
Portfolio
- BioSig Technologies
- Serve Robotics Inc
PD Theranostics
Viking Therapeutics
- Guerilla RF, Inc
- The NFT Gaming Company
- BioSig Technologies
Hoth Therapeutics
NLS Pharmaceutics
- Perfect Moment
NLS Pharmaceutics
- Silo Pharma
Amesite, Inc.
Perfect Moment
BioSig Technologies
- Odyssey Group
International Inc.
Soleno Therapeutics
Cohen & Steers
Amesite, Inc.
Pimco Access Income Fund
Cingulate, Inc.
- MEI
Pharma
- Voltron
Therapeutics
- Guggenheim Active Allocation Fund.
EyePoint Pharmaceuticals
aTyr Pharma Inc.
Blackrock ESG Capital Allocation Trust
BioSig Technologies
-
Perfect Moment
Aldeyra Therapeutics- Algorithm
Sciences
iCAD Inc.- Aerwave
Medical
- EyePoint Pharmaceuticals
Evoke Pharma
Affimed
Curis Inc.
Delcath Systems
Amesite, Inc
-
PD Theranostics
Arcturus Therapeutics
Soleno Therapeutics
- Voltron
Therapeutics
- ViralClear Pharmaceuticals
-
Amesite Inc
Delcath Systems
Arcturus Therapeutics
Hoth Therapeutics
- EyePoint Pharmaceuticals
BioSig Technologies
- Algorithm
Sciences
Ziopharm Oncology
Beyond Air
- Molecular
Templates, Inc.
Affimed
Soleno Therapeutics
Hoth Therapeutics
Noxopharm, Ltd
Icad, Inc
Athenex, Inc
- EyePoint Pharmaceuticals
Hoth Therapeutics
- Taiwan
Liposome Company
- Tiziana
Life Sciences
- Molecular
Templates, Inc.
- Viking
Therapeutics
Aldeyra Therapeutics
BioSig Technologies
- Aridis Pharmaceuticals
- WatchTower
Investments, LLC
Athenex, Inc
- Viking
Therapeutics
- MEI
Pharma
- Sesen
Bio
- Sesen
Bio
AIT Therapeutics
Hoth Therapeutics
Affimed
Gemphire
Athenex, Inc
- Fennec
Pharmaceuticals
- Cytori
Therapeutics
- Onconova
Therapeutics
ADMA Biologics
US Gold Corporation
- Asterias
Biotherapeutics
Flexion Therapeutics
Aldeyra Therapeutics- MabVax
Therapeutics, Inc
- SearchLight
Investments, LLC
- Spherix, Inc.
- Cooltech
Holding Corp.
- Repros
Therapeutics
- MabVax
Therapeutics, Inc
- Flexion
Therapeutics
- Onconova
Therapeutics
BioSig Technologies
AIT Therapeutics
- Therapix
Biosciences
- Gemphire
Function (x), Inc.
Aldeyra Therapeutics
Medovex Corporation
Affimed
- Pershing Gold Corporation
- Towersteam Corporation
- US Gold Corporation
FTE Networks, Inc.
- Protea Biosciences Group, Inc
- MabVax
Therapeutics, Inc
Spherix, Inc.
Alimera Sciences
ImmunoCellular
Gemphire
Flexion
PhaseRx
ADMA Biologics
Durect Corporation
- Medovex
Corporation
- ContraVir
Pharmaceuticals
- Pershing Gold Corporation
- Regenmed
Therapeutics
- Red Zone
Investments, LLC
Aspen University
- Aeolus
Pharmaceuticals
Cerecor, Inc.
- ContraVir
Pharmaceuticals
- MabVax Therapeutics, Inc
- Sevion
Therapeutics
- AirBase Technology
Partners, LLC
- Face-Off
Partners II, LLC
- Actinium
Pharmaceuticals
- Aldeyra
Therapeutics
- Viking
Therapeutics
- Pershing Gold Corporation
- BioSig
Technologies
- Protea
Biosciences Group, Inc
- MabVax
Therapeutics, Inc
ADMA Biologics
- Actinium
Pharmaceuticals
- Aldeyra
Therapeutics
- Medovex
Corporation
- Back Stage
Partners, LLC
- Mast
Therapeutics, Inc.
- Relmada
Therapeutics
- Cel-Sci
Corporation
- Pershing Gold Corporation
Spherix, Inc.
- Actinium
Pharmaceuticals
- Relmada
Therapeutics
- Cel-Sci
Corporation
- Cyclacel
Pharmaceuticals
- Marathon
Patent Group, Inc.
Spherix, Inc.
- NovaBay
Pharmaceuticals
- Bionic
Partners, LLC
- Private-I
Partners, LLC
Inventergy, Inc.
- Actinium
Pharmaceuticals
- Protea
Biosciences Group, Inc
- Cel-Sci
Corporation
ADMA Biologics
- T-Bird
Partners, LLC
- Cel-Sci
Corporation
- Relmada
Therapeutics
Alliqua
- Relmada
Therapeutics
- Boston
Therapeutics
- BioSig
Technologies
- AirLift
Investments, LLC
- Shire
Investments, LLC
- Actinium
Pharmaceuticals, Inc.
- Fusion Telecom-
munications Int'l, Inc.
- Bluebird Investment Partners
- Pre-Game
Partners, LLC
- Pre-Flight
Partners, LLC
- Pre-Market
Partners, LLC
- Social T
Partners, LLC
- Face-Off
Partners, LLC
- Chain-Link
Partners, LLC
Avada Slides
Portfolio Categories
Avada Sliders
Category
Page load link
